BioCentury | Aug 18, 2010
Top Story

Achillion raises $50.1 million

...treat HCV next month. ACH-1625 is a selective inhibitor of HCV NS3 protease . Achillion's elvucitabine...
BioCentury | Feb 22, 2010
Clinical News

Elvucitabine: Final Phase II data

...the double-blind, international Phase II ACH443-015 trial in 78 patients showed that 10 mg once-daily elvucitabine...
...for 300 mg Epivir lamivudine. Viral loads of <50 copies/mL were seen in 95% of elvucitabine...
...Viread. Achillion Pharmaceuticals Inc. (NASDAQ:ACHN), New Haven, Conn. Product: Elvucitabine ( ACH-443 , beta-L-Fd4C , ACH-126...
BioCentury | Feb 8, 2010
Company News

Achillion, GCA Therapeutics deal

...Achillion granted GCA an exclusive license to develop and commercialize elvucitabine to treat HBV and HIV...
BioCentury | Jan 23, 2010
Financial News

Achillion raises $21.4 million

...its share price was $2.60. Achillion was off $0.32 (12%) to $2.28 on Friday. Achillion's elvucitabine...
BioCentury | Jan 22, 2010
Financial News

Achillion planning offering

...Achillion said it would price the shares on Friday. Further terms were not disclosed. Achillion's elvucitabine...
BioCentury | Dec 18, 2008
Targets & Mechanisms

Second wind for T cells

...is developing small molecule therapeutics to treat HCV and HIV. The company's lead compound is elvucitabine...
BioCentury | Sep 18, 2008
Targets & Mechanisms

Targeting bacterial virulence

...to cause disease, without necessarily preventing the bacteria from colonizing or invading its host." Achillion's elvucitabine...
BioCentury | Aug 21, 2008
Tools & Techniques

Interfering with HIV

...multiple cellular and viral targets-you can multiplex targets in one treatment." Achillion's lead compound is elvucitabine...
...that the company said has higher potency and longer plasma half-life than comparable marketed molecules. Elvucitabine...
BioCentury | Aug 7, 2008
Financial News

Achillion seeking $31.1M financing

...ProQuest Investments and include Clarus Ventures and Investor Growth Capital. Lazard is placement agent. Achillion's elvucitabine...
BioCentury | Jun 16, 2008
Clinical News

Elvucitabine: Additional Phase II data

...data from the ongoing, double-blind, international Phase II ACH443-015 trial that showed 10 mg of elvucitabine...
...300 mg of Epivir lamivudine. Viral loads of <50 copies/mL were seen in 96% of elvucitabine...
...Calif.). Achillion Pharmaceuticals Inc. (NASDAQ:ACHN), New Haven, Conn. Product: Elvucitabine ( ACH-443 , beta-L-Fd4C , ACH-126...
Items per page:
1 - 10 of 51